One of the most promising medications in HHT is bevacizumab, a recombinant, humanized VEGF-A (vascular endothelial growth factor-A) targeting monoclonal antibody, which was the first approved angiogenesis inhibitor. This evidence concerns the gene VEGFA and hereditary hemorrhagic telangiectasia.